Return to Home

Zentalis Pharmaceuticals, Inc.

ZNTL

Find Out if You Qualify for a Financial Reward by filling out the form below.

Zentalis Pharmaceuticals, Inc. Form












Securities Fraud News does not share your information with others. There is no cost or obligation for you to submit.

Investigation Details

Zentalis announced on June 18, 2024, that “the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the following studies of azenosertib: the Phase 1 ZN-c3-001 dose-escalation study in solid tumors, the Phase 2 ZN-c3-005 (DENALI) study in platinum-resistant ovarian cancer (PROC) and the Phase 2 ZN-c3-004 (TETON) study in uterine serous carcinoma (USC).”

Following this news, Zentalis’s stock price fell over 50% on June 18, 2024.

Find More Cases

Ticker Symbol Company Name Join Deadline
APLT Applied Therapeutics, Inc. February 18, 2025 Join
BIOA BioAge Labs, Inc. March 10, 2025 Join
PCRX Pacira BioSciences, Inc. March 14, 2025 Join
NVO Novo Nordisk A/S March 25, 2025 Join
GO Grocery Outlet Holding Corp. March 31, 2025 Join
NEM Newmont Corporation April 01, 2025 Join
GSK GSK plc April 07, 2025 Join
NTLA Intellia Therapeutics, Inc. April 14, 2025 Join